

David R Freyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/134501/publications.pdf>

Version: 2024-02-01

147
papers

6,191
citations

66234

42
h-index

79541

73
g-index

150
all docs

150
docs citations

150
times ranked

6640
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2641-2647.	0.8	348
2	Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. <i>Journal of Clinical Oncology</i> , 2012, 30, 2408-2417.	0.8	298
3	Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 2548-2555.	0.6	275
4	Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications. <i>Journal of Pediatrics</i> , 1996, 129, 227-237.	0.9	269
5	Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. <i>Genetics in Medicine</i> , 2009, 11, 210-219.	1.1	259
6	Pleuropulmonary blastoma: A marker for familial disease. <i>Journal of Pediatrics</i> , 1996, 128, 220-224.	0.9	210
7	Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. <i>Lancet Oncology</i> , 2020, 21, 421-435.	5.1	167
8	Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 63-74.	5.1	159
9	Transition of Care for Young Adult Survivors of Childhood and Adolescent Cancer: Rationale and Approaches. <i>Journal of Clinical Oncology</i> , 2010, 28, 4810-4818.	0.8	158
10	Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. <i>Cancer</i> , 2016, 122, 988-999.	2.0	158
11	Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 1331-1337.	0.8	132
12	Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 5189-5194.	0.8	128
13	Models of care for survivors of childhood cancer. <i>Pediatric Blood and Cancer</i> , 2006, 46, 159-168.	0.8	125
14	Care of the Dying Adolescent: Special Considerations. <i>Pediatrics</i> , 2004, 113, 381-388.	1.0	122
15	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 725.	3.4	111
16	Metastatic Metanephric Adenoma in a Child. <i>American Journal of Surgical Pathology</i> , 2000, 24, 570-574.	2.1	107
17	Cancer survivorship practices, services, and delivery: a report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. <i>Journal of Cancer Survivorship</i> , 2011, 5, 345-357.	1.5	103
18	Understanding, measuring, and addressing the financial impact of cancer on adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27660.	0.8	92

#	ARTICLE	IF	CITATIONS
19	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1928-1936.	2.0	90
20	Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3932-3938.	0.6	78
21	The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment-related Cachexia. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 791-797.	0.3	77
22	Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2639-2645.	0.8	76
23	Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 440-445.	0.8	68
24	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 117, 3010-3015.	0.6	67
25	Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 138-145.	0.6	67
26	Child and adolescent self-report symptom measurement in pediatric oncology research: a systematic literature review. <i>Quality of Life Research</i> , 2018, 27, 291-319.	1.5	67
27	Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients. <i>Cancer</i> , 2013, 119, 4162-4169.	2.0	66
28	Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 141-150.	2.7	65
29	Successful nonoperative management of typhlitis in pediatric oncology patients. <i>Journal of Pediatric Surgery</i> , 2002, 37, 1151-1155.	0.8	63
30	Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. <i>Journal of Oncology Practice</i> , 2016, 12, e388-e395.	2.5	63
31	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 639-651.	0.6	62
32	Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors. <i>Clinical Cancer Research</i> , 2014, 20, 6314-6323.	3.2	61
33	Emerging Cancer Survival Trends, Disparities, and Priorities in Adolescents and Young Adults: A California Cancer Registry-Based Study. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz031.	1.4	60
34	Sexual functioning among young adult cancer patients: A 6-year longitudinal study. <i>Cancer</i> , 2018, 124, 398-405.	2.0	59
35	Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1143-1152.	3.0	59
36	Adolescent and young adult oncology: Transition of care. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1116-1119.	0.8	56

#	ARTICLE	IF	CITATIONS
37	Caseâ€linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Instituteâ€Designated comprehensive cancer center. <i>Cancer</i> , 2015, 121, 4398-4406.	2.0	55
38	The Clinical Trials Gap for Adolescents and Young Adults with Cancer: Recent Progress and Conceptual Framework for Continued Research. <i>Current Pediatrics Reports</i> , 2015, 3, 137-145.	1.7	53
39	Children's Oncology Group's 2013 blueprint for research: Adolescent and young adult oncology. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1055-1058.	0.8	52
40	Primary Primitive Neuroectodermal Tumor of the Spinal Cord Associated with Neural Tube Defect. <i>Pediatric Neurosurgery</i> , 1989, 15, 181-187.	0.4	50
41	Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patientâ€Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26261.	0.8	50
42	Supporting long-term follow-up of young adult survivors of childhood cancer: Correlates of healthcare self-efficacy. <i>Pediatric Blood and Cancer</i> , 2017, 64, 358-363.	0.8	47
43	A Reappraisal of Sex-Specific Cancer Survival Trends Among Adolescents and Young Adults in the United States. <i>Journal of the National Cancer Institute</i> , 2019, 111, 509-518.	3.0	46
44	Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention. <i>Cancer</i> , 2020, 126, 949-957.	2.0	44
45	Cancerâ€related followâ€up care among Hispanic and nonâ€Hispanic childhood cancer survivors: The Project Forward study. <i>Cancer</i> , 2015, 121, 605-613.	2.0	42
46	Sexual health among adolescent and young adult cancer survivors: A scoping review from the Children's Oncology Group Adolescent and Young Adult Oncology Discipline Committee. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 250-263.	157.7	40
47	Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. <i>Pediatric Blood and Cancer</i> , 2016, 63, 527-534.	0.8	38
48	In sickness and in health. <i>Cancer</i> , 2006, 107, 1702-1709.	2.0	37
49	The first step to integrating the child's voice in adverse event reporting in oncology trials: A content validation study among pediatric oncology clinicians. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1231-1236.	0.8	36
50	Hearing loss among survivors of childhood brain tumors treated with an irradiationâ€sparing approach. <i>Pediatric Blood and Cancer</i> , 2012, 58, 953-958.	0.8	35
51	Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 759-766.	0.6	35
52	Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 578-584.	2.7	33
53	Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial. <i>Blood Advances</i> , 2021, 5, 1853-1861.	2.5	32
54	Comparison of secondary and primary thyroid cancer in adolescents and young adults. <i>Cancer</i> , 2014, 120, 1155-1161.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies. <i>Seminars in Oncology</i> , 2015, 42, 740-747.	0.8	29
56	Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. <i>American Journal of Hematology</i> , 2018, 93, 1254-1266.	2.0	29
57	Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. <i>Cancer</i> , 2022, 128, 788-796.	2.0	29
58	Flow Cytometric Diagnosis of X-Linked Hyper-IgM Syndrome: Application of an Accurate and Convenient Procedure. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 363-370.	0.3	28
59	Substance use among adolescent and young adult cancer survivors. <i>Psycho-Oncology</i> , 2016, 25, 1357-1362.	1.0	28
60	Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1528-1533.	0.8	27
61	Characterization of Transfusion-Derived Iron Deposition in Childhood Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1913-1919.	1.1	27
62	Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 1623-1634.	0.8	27
63	Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 697-702.	0.8	26
64	Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2140-2149.	0.8	26
65	A prospective, observational cohort study comparing cancer clinical trial availability and enrollment between early adolescents/young adults and children. <i>Cancer</i> , 2018, 124, 983-990.	2.0	24
66	Treatment strategies for adolescent and young adult patients with acute myeloid leukemia. <i>Blood</i> , 2018, 132, 362-368.	0.6	24
67	Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. <i>Seminars in Oncology Nursing</i> , 2015, 31, 197-205.	0.7	20
68	Children with cancer: Special considerations in the discontinuation of life-sustaining treatment. <i>Medical and Pediatric Oncology</i> , 1992, 20, 136-142.	1.0	19
69	Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1277-1281.	0.8	19
70	Identifying metrics of success for transitional care practices in childhood cancer survivorship: A qualitative study of survivorship providers. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26587.	0.8	19
71	Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia. <i>JAMA Network Open</i> , 2020, 3, e2014205.	2.8	19
72	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. <i>Cancer Medicine</i> , 2020, 9, 2146-2152.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1109-1114.	1.1	17
74	Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. <i>Supportive Care in Cancer</i> , 2018, 26, 1305-1313.	1.0	17
75	Barriers and Facilitators to Adolescent and Young Adult Cancer Trial Enrollment: NCORP Site Perspectives. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab027.	1.4	17
76	Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials. <i>Cancer Medicine</i> , 2018, 7, 2951-2959.	1.3	16
77	Evaluating and providing quality health information for adolescents and young adults with cancer. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27931.	0.8	16
78	Transitional care practices, services, and delivery in childhood cancer survivor programs: A survey study of U.S. survivorship providers. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27793.	0.8	16
79	Exercise Recommendations for Childhood Cancer Survivors Exposed to Cardiotoxic Therapies. <i>Journal of Pediatric Oncology Nursing</i> , 2012, 29, 246-252.	1.5	15
80	A prospective comparison of cancer clinical trial availability and enrollment among adolescents/young adults treated at an adult cancer hospital or affiliated children's hospital. <i>Cancer</i> , 2018, 124, 4064-4071.	2.0	15
81	Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure. <i>Cancer</i> , 2021, 127, 1483-1494.	2.0	15
82	Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials. <i>Cancer</i> , 2021, 127, 3664-3670.	2.0	15
83	Infrastructure of Fertility Preservation Services for Pediatric Cancer Patients: A Report From the Children's Oncology Group. <i>JCO Oncology Practice</i> , 2022, 18, e325-e333.	1.4	15
84	Prevention of Hearing Loss in Children Receiving Cisplatin Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 317-318.	0.8	14
85	Young adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen do not need a bone marrow transplant in first remission. <i>Blood</i> , 2013, 121, 5253-5255.	0.6	14
86	Depressive Symptoms and Quality of Life Among Adolescent and Young Adult Cancer Survivors: Impact of Gender and Latino Culture. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 384-388.	0.7	14
87	Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research. <i>Cancer</i> , 2020, 126, 140-147.	2.0	14
88	Estimating cancer treatment intensity from SEER cancer registry data: methods and implications for population-based registry studies of pediatric cancers. <i>Cancer Causes and Control</i> , 2020, 31, 881-890.	0.8	14
89	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	3.4	14
90	Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective. <i>BMC Medical Research Methodology</i> , 2013, 13, 154.	1.4	13

#	ARTICLE	IF	CITATIONS
91	A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2370-2378.	0.6	13
92	The Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network: A New Model for Addressing Site-Level Factors Impacting Clinical Trial Enrollment. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 522-527.	0.7	13
93	Project Forward: A Population-Based Cohort Among Young Adult Survivors of Childhood Cancers. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab068.	1.4	13
94	Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431. <i>Lancet Oncology</i> , The, 2022, 23, 570-572.	5.1	13
95	Cognitive outcomes among Latino survivors of childhood acute lymphoblastic leukemia and lymphoma: A cross-sectional cohort study using culturally competent, performance-based assessment. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26844.	0.8	12
96	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. <i>Blood</i> , 2011, 118, 1510-1510.	0.6	12
97	Obesity and Risk for Second Malignant Neoplasms in Childhood Cancer Survivors: A Case-Control Study Utilizing the California Cancer Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1612-1620.	1.1	11
98	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. <i>Oncologist</i> , 2022, 27, 579-586.	1.9	11
99	Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials. <i>Scientific Reports</i> , 2022, 12, 3875.	1.6	11
100	Development of a Culturally Competent Service to Improve Academic Functioning for Latino Survivors of Acute Lymphoblastic Leukemia: Methodological Considerations. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 222-229.	1.5	10
101	Sodium Thiosulfate and Cisplatin-Induced Hearing Loss. <i>New England Journal of Medicine</i> , 2018, 379, 1180-1181.	13.9	10
102	Identifying metrics of success for transitional care practices in childhood cancer survivorship: A qualitative interview study of parents. <i>Cancer Medicine</i> , 2021, 10, 6239-6248.	1.3	10
103	Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors. <i>Cancers</i> , 2021, 13, 4045.	1.7	10
104	A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. <i>Journal of Neuro-Oncology</i> , 2018, 140, 575-582.	1.4	9
105	Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab039.	1.4	9
106	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 229-233.	0.7	9
107	Pediatric oncology clinician communication about sexual health with adolescents and young adults: A report from the children's oncology group. <i>Cancer Medicine</i> , 2021, 10, 5110-5119.	1.3	9
108	<i>DNMT3A</i> overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults. <i>Blood</i> , 2022, 139, 461-464.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 536-542.	1.1	9
110	Long-term follow-up of endocrine function among young children with newly diagnosed malignant central nervous system tumors treated with irradiation-avoiding regimens. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26616.	0.8	8
111	A Population-Based Analysis of 30-Year Mortality among Five-Year Survivors of Adolescent and Young Adult Cancer: The Roles of Primary Cancer, Subsequent Malignancy, and Other Health Conditions. <i>Cancers</i> , 2021, 13, 3956.	1.7	7
112	Childhood Cancer Survivorship and Substance Use Behaviors: A Matched Case-Control Study Among Hispanic Adolescents and Young Adults. <i>Journal of Adolescent Health</i> , 2018, 63, 115-117.	1.2	6
113	Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 696-696.	0.6	6
114	Profiles of emotional distress and growth among adolescents and young adults with cancer: A longitudinal study.. <i>Health Psychology</i> , 2020, 39, 370-380.	1.3	6
115	A parent-directed intervention for addressing academic risk in Latino survivors of childhood leukemia: results of a pilot study. <i>Psycho-Oncology</i> , 2016, 25, 1246-1249.	1.0	5
116	Insurance coverage change and survivorship care among young adult survivors of childhood cancer. <i>Health Services Research</i> , 2022, 57, 159-171.	1.0	5
117	Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,. <i>Blood</i> , 2011, 118, 3574-3574.	0.6	5
118	Institutional Adherence to Cardiovascular Risk Factor Screening Guidelines for Young Survivors of Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e253-e257.	0.3	4
119	Early Cardiac Iron Overload in a Child on Treatment of Acute Lymphoblastic Leukemia. <i>Pediatrics</i> , 2015, 136, e697-e700.	1.0	4
120	Reconsidering Physical Activity Restrictions for Mononephric Survivors of Childhood Cancer. <i>Journal of Pediatric Oncology Nursing</i> , 2016, 33, 306-313.	1.5	4
121	Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network. <i>JCO Oncology Practice</i> , 2022, 18, 224-231.	1.4	4
122	Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28647.	0.8	3
123	Surveillance for radiation-related late effects in childhood cancer survivors: The impact of using volumetric dosimetry. <i>Cancer Medicine</i> , 2021, 10, 905-913.	1.3	3
124	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 445-452.	1.3	3
125	Survivorship Transitions Following Childhood and Adolescent Cancer. <i>Pediatric Oncology</i> , 2015, , 413-424.	0.5	2
126	Promoting Health and Care Transitions in the Long-Term AYA Survivor. <i>Pediatric Oncology</i> , 2017, , 711-733.	0.5	2

#	ARTICLE	IF	CITATIONS
127	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 363-370.	1.9	2
128	Response to Siegel et al.. <i>Journal of the National Cancer Institute</i> , 2019, 111, 635-636.	3.0	1
129	Significantly Increased Risk of Grade II-IV Acute Gvhd in Adolescent and Young Adult (AYA) Recipients (ages ≥ 13 years) Vs Childhood Recipients (ages 2-12 years) with Acute Leukemia Following Matched Unrelated Donor (MUD) Stem Cell Transplantation (SCT): The Children's Oncology Group Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S184.	2.0	1
130	Prevalence of fertility discussions between young adult colorectal cancer survivors and their providers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3518-3518.	0.8	1
131	Adverse Effects of Cancer Treatment on Hearing. <i>Pediatric Oncology</i> , 2015, , 131-149.	0.5	1
132	Age but Not Adiposity Predicts Asparaginase-Induced Hepatotoxicity during Induction Therapy for Adolescent and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2662-2662.	0.6	1
133	Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorship Consortium in Southern California. <i>Cureus</i> , 2022, 14, e21981.	0.2	1
134	Integrating primary care and childhood cancer survivorship care: a scoping review protocol. <i>BMJ Open</i> , 2022, 12, e059050.	0.8	1
135	Measuring the impact of dexrazoxane cardioprotection. <i>Pediatric Blood and Cancer</i> , 2007, 48, 483-484.	0.8	0
136	MB-101 TOXICITY AND OUTCOME IN ADOLESCENT AND YOUNG ADULTS (AYA) TREATED FOR MEDULLOBLASTOMA (MB) AND PRIMITIVE NEUROECTODERMAL TUMORS (PNET) ON COG-A9961 AND CCG-99701: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG). <i>Neuro-Oncology</i> , 2016, 18, iii120.1-iii120.	0.6	0
137	2437 A prospective study of cancer clinical trial availability and enrollment among adolescents/young adults treated at a Children's Hospital or Affiliated Adult Cancer Specialty Hospital. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 37-37.	0.3	0
138	Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 34-34.	0.8	0
139	Association of language proficiency, sociodemographics, and neurocognitive functioning in dual-language Latino survivors of childhood acute lymphoblastic leukemia and lymphoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29118.	0.8	0
140	Impact of using volumetric dosimetry to screen childhood cancer survivors for radiation-related late effects.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12066-12066.	0.8	0
141	Patterns of Cancer Care and Association with Survival among Younger Adolescents and Young Adults: A Population-Based Retrospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2105-2113.	1.1	0
142	The Long and Winding Road: Transitions in Care for the Childhood Cancer Survivor. , 2015, , 3-16.		0
143	Considerations for Improving Care and Outcomes of Adolescents and Young Adults Undergoing Hematopoietic Cell Transplantation. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2020, , 141-156.	0.0	0
144	Survival of Adolescents and Young Adults with Prevalent Poor-Prognosis Metastatic Cancers: A Population-based Study of Contemporary Patterns and Their Implications. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , cebp.0913.2021.	1.1	0

#	ARTICLE	IF	CITATIONS
145	Patient care satisfaction and emergency room utilization among young adult colorectal cancer survivors during the SARS-CoV-2 pandemic.. Journal of Clinical Oncology, 2022, 40, 34-34.	0.8	0
146	Prevalence of information needs among emerging and young adult colorectal cancer survivors.. Journal of Clinical Oncology, 2022, 40, 71-71.	0.8	0
147	Gaps in adolescent and young adult oncology education during medical and pediatric hematology/oncology fellowship training.. Journal of Clinical Oncology, 2022, 40, 11026-11026.	0.8	0